Approved indications (U.S.)
Daptomycin IV is approved to treat: (1) complicated skin and skin structure infections caused by susceptible Gram-positive bacteria in adults and in children 1–17 years old; and (2) Staphylococcus aureus bloodstream infections (bacteremia) in adults and children 1–17 years old, including right-sided infective endocarditis due to S. aureus in adults.

Common off-label uses
Clinicians also use daptomycin off label, often in combination with other antibiotics, for infections such as left-sided native valve endocarditis when standard therapy (e.g., vancomycin) fails or cannot be used, bacteremia or endocarditis caused by vancomycin-resistant Enterococcus (VRE), prosthetic joint infections, and vertebral osteomyelitis; evidence for these uses is mainly from observational studies, case series, and expert guidelines rather than large randomized trials.

Efficacy expectations
For skin infections, fever and pain often begin to improve within 2–3 days of starting effective therapy, with full resolution over 1–2 weeks depending on severity and source control. In bloodstream infection or endocarditis, clearing of bacteria and improvement in symptoms typically take several days and depend heavily on removal of infected devices and drainage of abscesses. When used appropriately against susceptible organisms, daptomycin has cure rates comparable to or better than vancomycin for many serious Gram-positive infections, but it is not effective for pneumonia because lung surfactant inactivates the drug.

Typical adult dosing and route
Daptomycin is given only by the intravenous route. For adults with complicated skin and skin structure infections, the usual dose is 4 mg/kg IV once every 24 hours for 7–14 days. For Staphylococcus aureus bloodstream infection or right-sided endocarditis, 6 mg/kg IV once every 24 hours is typical, often for 2–6 weeks depending on the source and clinical response.

• In adults, the dose can be administered as a 30‑minute IV infusion or a 2‑minute IV injection (push), according to institutional practice.
• In patients with significant renal impairment (creatinine clearance < about 30 mL/min, including dialysis), the same weight‑based dose is usually given every 48 hours instead of every 24 hours.

Pediatric dosing (1–17 years)
Doses for children are higher on a mg/kg basis and vary by age and indication. For complicated skin infections, once‑daily IV doses range approximately from 5 mg/kg in adolescents up to around 10 mg/kg in toddlers, given for up to 14 days. For S. aureus bacteremia, pediatric regimens use higher mg/kg doses and may extend up to 42 days depending on the infection and response. In children 1–6 years old, daptomycin is infused over 60 minutes, and in those 7–17 years old over 30 minutes; IV push dosing is not used in pediatrics.

Administration details and special instructions
Daptomycin is usually given in the hospital or in an outpatient infusion setting by trained staff. It is infused in normal saline, and no food adjustments are needed because it is not taken by mouth. It should not be used to treat pneumonia because lung surfactant inactivates the drug. Renal function and CPK levels should be checked regularly during treatment, especially with prolonged therapy, high doses, or concomitant myotoxic drugs.

Missed dose guidance
If a scheduled IV dose is missed, the patient (or caregiver) should contact the treating team or infusion center as soon as possible; the dose is typically given as soon as it can be safely administered, and subsequent doses may be rescheduled to restore the once‑daily or every‑other‑day pattern rather than doubled.

Overdose management
There is no specific antidote for daptomycin overdose. Management is supportive and includes close monitoring of kidney function, CPK levels, and for muscle or respiratory symptoms; hemodialysis can remove some drug but is not fully effective. Any suspected overdose should prompt urgent medical evaluation.

Common side effects
Frequently reported side effects include headache, nausea, vomiting, diarrhea, constipation, rash, injection-site reactions, and increases in blood creatine phosphokinase (CPK), which can reflect muscle irritation. These effects are usually mild to moderate and often appear within the first days to weeks of therapy.

• Mild muscle aches or weakness without large CPK elevations can occur and should be reported to the healthcare team.
• Some patients develop reversible elevations in liver enzymes or changes in kidney tests, especially if they have pre‑existing organ dysfunction or are on other nephrotoxic drugs.

Serious or rare adverse effects
Serious muscle injury (myopathy or rhabdomyolysis) can occur, particularly at higher doses or when combined with other drugs that affect muscles (such as statins or fibrates); this may present as severe muscle pain, weakness, or dark urine and requires urgent evaluation. A rare but important reaction is eosinophilic pneumonia, typically developing after 2 or more weeks of therapy, with symptoms such as new or worsening cough, fever, shortness of breath, and new lung infiltrates on imaging. Other uncommon but serious events include peripheral neuropathy, allergic or anaphylactic reactions, Clostridioides difficile–associated diarrhea, and kidney injury.

Warnings and precautions
Muscle toxicity: baseline and at least weekly CPK monitoring is recommended in most patients, with more frequent checks if they have renal impairment or are taking statins or other myotoxic drugs; the drug is usually stopped if symptomatic CPK elevations occur. Renal impairment: dosing intervals must be extended when creatinine clearance is markedly reduced or in dialysis patients. Daptomycin is not recommended in infants younger than 1 year because of potential effects on muscles and the nervous system seen in animal studies. Use in pregnancy and breastfeeding is based on limited human data; it is generally reserved for situations where the expected benefit outweighs potential risks, and infants should be monitored for gastrointestinal or feeding issues if exposed via breast milk.

Relative safety compared with similar drugs
Compared with vancomycin, daptomycin tends to cause less kidney toxicity but has a higher concern for muscle-related side effects and requires routine CPK monitoring. It has minimal drug–drug interactions via liver enzyme pathways and does not significantly affect the heart rhythm, which distinguishes it from some other agents used for resistant Gram-positive infections.

Reporting side effects and safety updates (U.S.)
Patients and clinicians can report suspected side effects to the FDA MedWatch program and review the latest safety alerts and prescribing information on the FDA’s website or through official prescribing resources.

Drug and supplement interactions
Daptomycin has few interactions via liver enzyme systems, but it can interact functionally with other agents that affect muscles or kidneys. Statins (HMG‑CoA reductase inhibitors), fibrates, and other myotoxic drugs increase the risk of muscle injury and CPK elevation; many clinicians temporarily hold statins while patients are on daptomycin. Concomitant use with other nephrotoxic agents (such as high‑dose diuretics, aminoglycosides, or some chemotherapies) may increase the risk of kidney dysfunction and typically requires closer monitoring. No specific food or alcohol interactions are known, although limiting alcohol is prudent in patients with liver or muscle concerns.

Effects on laboratory tests and procedures
Daptomycin can cause falsely elevated prothrombin time (PT) and INR values with certain laboratory reagents, especially in patients also receiving warfarin, so alternative assays or repeat testing may be needed if results do not match the clinical picture. No specific interactions with imaging contrast agents or common diagnostic procedures are established.

Precautions and situations requiring caution
Use requires caution in patients with pre‑existing muscle disorders, prior statin‑associated myopathy, or uncontrolled hypothyroidism, as they may be more prone to muscle injury. In patients with moderate to severe renal impairment, doses must be adjusted and CPK and renal function monitored more closely. Daptomycin is not recommended for infants younger than 1 year. In pregnancy and breastfeeding, use is generally reserved for serious infections when safer alternatives are not suitable, with careful monitoring of the mother and infant.

Monitoring needs
Baseline and at least weekly CPK and renal function tests are recommended during therapy, with more frequent monitoring for patients receiving statins or other myotoxic or nephrotoxic agents, those on high doses, or those with prolonged courses. Clinicians also monitor for new or worsening muscle pain or weakness, respiratory symptoms that might suggest eosinophilic pneumonia, and signs of peripheral neuropathy.

Q: What infections is daptomycin used to treat?
A: Daptomycin is used to treat serious infections caused by certain Gram-positive bacteria, especially complicated skin and soft‑tissue infections and Staphylococcus aureus bloodstream infections (including some cases of right‑sided endocarditis), and is sometimes used off label for difficult infections like VRE bacteremia or bone and joint infections.

Q: Why can’t daptomycin be used for pneumonia?
A: Daptomycin is inactivated by lung surfactant, a natural substance that lines the air sacs in the lungs, so it cannot reach effective activity in lung tissue and does not reliably cure pneumonia.

Q: How quickly will I start to feel better on daptomycin?
A: Many people with skin infections begin to notice improvement in fever, pain, and redness within 2–3 days, but serious bloodstream or heart infections may take longer to improve and require weeks of therapy plus procedures such as drainage or removal of infected devices.

Q: Is daptomycin safer or more effective than vancomycin?
A: For susceptible Gram‑positive infections, daptomycin is generally as effective as vancomycin and may be preferred when vancomycin cannot be used or has failed; it tends to cause less kidney injury but has a greater focus on monitoring for muscle problems, so the choice depends on the specific infection and patient risks.

Q: Can I stay on my cholesterol medicine (statin) while getting daptomycin?
A: Because both daptomycin and statins can affect muscles, your clinician may temporarily stop the statin or monitor CPK levels more closely while you are receiving daptomycin; you should not change your statin on your own without discussing it with your healthcare team.